查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2128503

性傳染病檢測市場：規模、佔有率、成長、全球產業分析、區域趨勢及2026年至2034年預測

Sexually Transmitted Diseases Testing Market Size, Share, Growth and Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 162 Pages | 商品交期: 2-3個工作天內

價格

性傳染病檢測市場的成長要素

全球性傳染病檢測市場在2025年達到110.7億美元，預計從2026年的119.7億美元成長至2034年的239.5億美元，預測期內CAGR為9.10%。性傳染病盛行率上升、公眾對早期診斷的認知提高以及政府擴大定期篩檢推廣力度是推動市場成長的主要因素。北美地區憑藉先進的醫療基礎設施、有利的保險償付政策和廣泛的宣傳宣傳活動，在2025年佔據全球市場42.80%的佔有率。

性傳染病感染仍然是全球範圍內的重大公共衛生問題。許多感染疾病，包括披衣菌感染、淋病、梅毒、愛滋病毒（HIV）和人類乳突病毒（HPV）感染，在早期階段往往無症狀，因此及時檢測對於預防感染傳播和確保有效治療非常重要。分子診斷、快速即時檢測（POC）和自動化檢測系統的技術進步顯著提高了檢測的準確性和可近性。各國政府和醫療機構加大對性傳染病篩檢計畫的投入，進一步加速了市場成長。

性傳染病感染率的上升推動市場成長。

已開發國家和開發中國家性傳染病病例的不斷增加是推動性傳染病檢測市場成長要素之一。根據世界衛生組織統計，每年新增感染病例數百萬例，導致對診斷試劑盒、試劑和檢測設備的持續需求。生活方式的改變、無保護性行為、某些地區缺乏相關知識以及都市化加快等因素，都加劇了疾病負擔。

世界各國政府和非營利組織正積極透過宣傳宣傳活動、免費檢測計畫和教育活動，推廣定期進行性傳染病感染篩檢。例如，印度的「安全診所」（Suraksha Clinic）和巴西的公共衛生舉措等計畫，顯著改善了人們獲得檢測服務的途徑。這些努力推動檢測量的增加，並促進先進診斷技術在全球的普及。

即時檢測已成為一大趨勢。

性傳染病檢測市場最顯著的趨勢之一是從傳統的檢查室檢測迅速轉向即時診斷。即時檢測能夠更快地得出結果，縮短等待時間，儘早開始治療，並最大限度地減少感染疾病傳播。這些檢測方法正擴大應用於醫院、診所、藥局、社區健康中心，甚至在家庭環境中。

快速分子診斷和攜帶式檢測設備的進步提高了性傳染病檢測的可近性，同時降低了檢測成本。家用檢測套組也因其更高的隱私性以及能夠消除與性傳染病診斷相關的社會污名而日益普及。預計在整個預測期內，對便捷快速檢測解決方案日益成長的需求將持續帶來巨大的成長機會。

市場挑戰包括社會歧視和低檢測率。

儘管檢測技術取得了顯著進步，但人們不願意接受性傳染病檢測仍然是一項重大挑戰。社會污名、隱私顧慮、性健康意識不足以及諮詢服務匱乏等因素，仍阻礙許多人及時獲得診斷。此外，在某些高風險族群中，對歧視的恐懼和醫療資源的匱乏導致檢測率持續偏低。

儘管政府的宣傳活動提高了檢測率，但許多發展中地區仍然面臨許多挑戰，例如訓練有素的專業人員短缺、診斷基礎設施不足以及缺乏價格合理的檢測服務。克服這些障礙對於實現更廣泛的疾病控制和維持長期市場成長非常重要。

披衣菌感染檢測和試劑/試劑盒推動市場區隔。

依產品類型分類，試劑和試劑盒細分市場預計將成為市場成長的主要驅動力，預計到2026年將佔據 79.32%的市場佔有率。診斷測試數量的增加、耗材的頻繁使用以及先進分子診斷試劑盒的不斷推出，推動該細分市場的成長。

依應用領域分類，披衣菌感染檢測預計將在2026年佔據最大的市場佔有率，達到24.47%，這主要得益於其全球高流行率、公眾意識的不斷提高以及價格合理的診斷產品的普及。就檢測環境而言，檢查室檢測預計將繼續保持主導地位，在2026年佔據78.33%的市場佔有率，這主要歸功於其卓越的準確性和在醫療機構的廣泛應用。診斷中心憑藉先進的檢測基礎設施和日益成長的患者需求，預計仍將是主要的終端用戶群體，在2026年佔據全球市場52.34%的佔有率。

北美市場持續維持領先地位，而亞太地區市場也呈現強勁成長動能。

北美市場規模在2025年達到47.4億美元，預計2026年達到51.4億美元。由於政府主導的強力的舉措、官民合作關係、廣泛的疾病意識以及先進的診斷基礎設施，北美有望保持其主導地位。美國透過廣泛的篩檢計畫和持續的技術創新，持續推動區域需求。

歐洲仍然是第二大區域市場，這得益於先進的檢測能力、訓練有素的醫療保健專業人員以及創新檢測技術的日益普及。同時，亞太地區預計將在長期內實現最快成長，這主要得益於醫療基礎設施的不斷完善、政府宣傳宣傳活動的活性化、性傳染病感染發病率的上升，以及中國、印度和日本等國家獲得價格合理的診斷服務的便利程度提高。

目錄

第1章 引言

第2章 執行摘要

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機會
  • 市場趨勢

第4章 主要考察

  • 主要國家主要疾病盛行率（2025年）
  • 主要行業趨勢
  • 主要國家和地區監管狀況概述
  • 性傳染病檢測市場的技術進步
  • 新冠疫情的影響：全球性傳染病檢測市場

第5章 2021-2034年全球性傳染病檢測市場分析、洞察與預測

  • 市場分析、洞察與預測：依產品類型分類
    • 裝置
    • 試劑和檢測套組
  • 市場分析、洞察與預測：依應用領域分類
    • 披衣菌感染
    • 梅毒
    • 生殖器皰疹
    • 淋病
    • 人類免疫力缺乏病毒（HIV）
    • 人類乳突病毒（HPV）
    • 其他
  • 市場分析、洞察與預測：依設施類型分類
    • 臨床檢測
    • 即時偵測（POC）
  • 市場分析、洞察與預測：依最終用戶分類
    • 醫院和診所
    • 診斷中心
    • 其他
  • 市場分析、洞察與預測：依地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章 北美性傳染病檢測市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章 歐洲性傳染病檢測市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪地那維亞
    • 其他歐洲國家

第8章 亞太地區性傳染病檢測市場分析、洞察與預測（2021-2034年）

  • 國家
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家

第9章 拉丁美洲性傳染病檢測市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章 中東和非洲性傳染病檢測市場分析、洞察與預測（2021-2034年）

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市場佔有率分析（2025年）
  • 公司簡介
    • Abbott
    • F. Hoffmann-La Roche Ltd
    • Becton, Dickinson and Company（BD）
    • Hologic, Inc.
    • Danaher Corporation
    • Thermo Fisher Scientific Inc.
    • bioMerieux, Inc.
    • Bio-Rad Laboratories, Inc.
    • DiaSorin Inc.
Product Code: FBI101095

Growth Factors of sexually transmitted diseases (STD) testing Market

The global sexually transmitted diseases (STD) testing market was valued at USD 11.07 billion in 2025 and is projected to grow from USD 11.97 billion in 2026 to USD 23.95 billion by 2034, registering a CAGR of 9.10% during the forecast period. The increasing prevalence of sexually transmitted infections (STIs), rising public awareness about early diagnosis, and growing government initiatives promoting routine screening are major factors supporting market expansion. North America dominated the global market with a 42.80% share in 2025, driven by advanced healthcare infrastructure, favorable reimbursement policies, and extensive awareness campaigns.

Sexually transmitted diseases remain a major public health concern worldwide. Many infections, including chlamydia, gonorrhea, syphilis, HIV, and human papillomavirus (HPV), often remain asymptomatic during the early stages, making timely testing essential for preventing transmission and ensuring effective treatment. Technological advancements in molecular diagnostics, rapid point-of-care (POC) testing, and automated laboratory systems are significantly improving testing accuracy and accessibility. Increasing investments by governments and healthcare organizations to strengthen STI screening programs are further accelerating market growth.

Rising Incidence of Sexually Transmitted Infections Driving Market Growth

The increasing number of sexually transmitted infections across both developed and developing countries is one of the strongest growth drivers for the STD testing market. According to global health organizations, millions of new infections occur annually, creating sustained demand for diagnostic kits, reagents, and laboratory instruments. Factors such as changing lifestyles, unprotected sexual practices, limited awareness in certain regions, and growing urbanization continue to contribute to the increasing disease burden.

Governments and non-profit organizations are actively promoting routine STI screening through awareness campaigns, free testing programs, and educational initiatives. Programs such as India's Suraksha Clinics and Brazil's public health initiatives have significantly improved access to testing services. These efforts are increasing testing volumes and supporting the widespread adoption of advanced diagnostic technologies worldwide.

Growing Shift toward Point-of-Care Testing Emerges as a Major Trend

One of the most significant trends shaping the STD testing market is the rapid transition from conventional laboratory-based testing to point-of-care diagnostics. Point-of-care tests provide faster results, reduce waiting times, improve treatment initiation, and minimize disease transmission. These tests are increasingly being adopted across hospitals, physician clinics, pharmacies, community health centers, and even home-based settings.

Advancements in rapid molecular diagnostics and portable testing devices are making STD testing more accessible while reducing costs. Home-based testing kits are also gaining popularity as they offer greater privacy and help overcome the social stigma associated with STI diagnosis. This growing preference for convenient and rapid testing solutions is expected to remain a major growth opportunity throughout the forecast period.

Market Challenges Include Social Stigma and Low Testing Rates

Despite significant improvements in testing technologies, reluctance toward STI testing remains a major challenge. Social stigma, confidentiality concerns, lack of sexual health awareness, and inadequate counseling services continue to discourage many individuals from seeking timely diagnosis. Certain high-risk populations also remain under-tested due to fear of discrimination and limited healthcare accessibility.

Although government awareness programs have improved testing rates, many developing regions still face shortages of trained professionals, diagnostic infrastructure, and affordable testing services. Addressing these barriers will be essential to achieving broader disease control and sustaining long-term market growth.

Chlamydia Testing and Reagents & Kits Lead Market Segments

Based on product type, the reagents & kits segment is expected to dominate the market with a 79.32% share in 2026. The increasing volume of diagnostic testing, frequent use of consumables, and continuous introduction of advanced molecular testing kits are driving segment growth.

By application, chlamydia testing is projected to account for the largest market share of 24.47% in 2026 due to its high global prevalence, increasing awareness, and availability of affordable diagnostic products. Laboratory testing will continue to dominate testing settings with a 78.33% market share in 2026, owing to its superior accuracy and widespread availability in healthcare facilities. Diagnostic centers are expected to remain the leading end-user segment, accounting for 52.34% of the global market in 2026, supported by advanced laboratory infrastructure and increasing patient preference.

North America Maintains Market Leadership while Asia Pacific Shows Strong Growth

North America generated USD 4.74 billion in 2025 and is expected to reach USD 5.14 billion in 2026, maintaining its leadership due to strong government initiatives, public-private partnerships, widespread disease awareness, and advanced diagnostic infrastructure. The U.S. continues to dominate regional demand through extensive screening programs and continuous technological innovation.

Europe remains the second-largest regional market, supported by advanced laboratory capabilities, skilled healthcare professionals, and increasing adoption of innovative testing technologies. Meanwhile, Asia Pacific is expected to witness the fastest long-term growth due to expanding healthcare infrastructure, rising government awareness campaigns, increasing STI prevalence, and improved access to affordable diagnostic services across countries such as China, India, and Japan.

Competitive Landscape

The global STD testing market remains highly competitive, with leading companies investing heavily in product innovation, strategic collaborations, geographic expansion, and research & development. Major industry participants include F. Hoffmann-La Roche Ltd., Abbott, BD, Hologic, Inc., Thermo Fisher Scientific Inc., bioMerieux, Cepheid (Danaher Corporation), Bio-Rad Laboratories, Inc., and DiaSorin S.p.A.

Recent industry developments continue to strengthen market competition. In February 2023, Roche partnered with the U.S. CDC under the Lab Networks for Health initiative to improve HIV and tuberculosis detection globally. Thermo Fisher Scientific introduced its Applied Biosystems HIV-1 Genotyping Kit, while Mylab Discovery Solutions launched rapid diagnostic kits for HIV, Hepatitis C, and Syphilis. These innovations are expanding testing capabilities and improving early disease detection worldwide.

Conclusion

The global sexually transmitted diseases testing market is positioned for strong and sustained growth through 2034, supported by increasing disease prevalence, expanding government screening initiatives, technological advancements in molecular diagnostics, and the growing adoption of rapid point-of-care testing. Although social stigma and testing reluctance continue to present challenges, ongoing investments in public health awareness, affordable diagnostic solutions, and innovative testing technologies are expected to improve early diagnosis rates. As healthcare systems increasingly prioritize preventive screening and accessible sexual health services, the STD testing market is set to play a vital role in reducing disease transmission and improving global public health.

Segmentation By Product Type, Application, Setting, End User, and Region

By Product Type * Instruments

  • Reagents & Kits

By Application * Chlamydia

  • Syphilis
  • Genital Herpes
  • Gonorrhea
  • Human Immunodeficiency Virus
  • Human Papillomavirus
  • Others

By Setting * Laboratory Testing

  • Point-of-Care

By End User * Hospital & Clinics

  • Diagnostic Centers
  • Others

By Region * North America (By Product Type, By Application, By Setting, By End User, By Country)

    • U.S.
    • Canada
  • Europe (By Product Type, By Application, By Setting, By End User, By Country/Sub-Region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Product Type, By Application, By Setting, By End User, By Country/Sub-Region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Product Type, By Application, By Setting, By End User, By Country/ Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Product Type, By Application, By Setting, By End User, By Country/Sub-Region)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Diseases, By Key Countries, 2025
  • 4.2. Key Industry Developments
  • 4.3. Overview of Regulatory Scenario, By Key Countries/Regions
  • 4.4. Technological Advancements in Sexually Transmitted Diseases Testing Market
  • 4.5. Impact of COVID-19 on Global Sexually Transmitted Diseases Testing Market

5. Global Sexually Transmitted Diseases Testing Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product Type
    • 5.1.1. Instruments
    • 5.1.2. Reagents & Kits
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Chlamydia
    • 5.2.2. Syphilis
    • 5.2.3. Genital Herpes
    • 5.2.4. Gonorrhea
    • 5.2.5. Human Immunodeficiency Virus
    • 5.2.6. Human Papillomavirus (HPV)
    • 5.2.7. Others
  • 5.3. Market Analysis, Insights and Forecast - By Setting
    • 5.3.1. Laboratory Testing
    • 5.3.2. Point-of Care (POC)
  • 5.4. Market Analysis, Insights and Forecast - By End User
    • 5.4.1. Hospitals and Clinics
    • 5.4.2. Diagnostic Centers
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Sexually Transmitted Diseases Testing Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product Type
    • 6.1.1. Instruments
    • 6.1.2. Reagents & Kits
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Chlamydia
    • 6.2.2. Syphilis
    • 6.2.3. Genital Herpes
    • 6.2.4. Gonorrhea
    • 6.2.5. Human Immunodeficiency Virus
    • 6.2.6. Human Papillomavirus (HPV)
    • 6.2.7. Others
  • 6.3. Market Analysis, Insights and Forecast - By Setting
    • 6.3.1. Laboratory Testing
    • 6.3.2. Point-of Care (POC)
  • 6.4. Market Analysis, Insights and Forecast - By End User
    • 6.4.1. Hospitals and Clinics
    • 6.4.2. Diagnostic Centers
    • 6.4.3. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Sexually Transmitted Diseases Testing Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product Type
    • 7.1.1. Instruments
    • 7.1.2. Reagents & Kits
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Chlamydia
    • 7.2.2. Syphilis
    • 7.2.3. Genital Herpes
    • 7.2.4. Gonorrhea
    • 7.2.5. Human Immunodeficiency Virus
    • 7.2.6. Human Papillomavirus (HPV)
    • 7.2.7. Others
  • 7.3. Market Analysis, Insights and Forecast - By Setting
    • 7.3.1. Laboratory Testing
    • 7.3.2. Point-of Care (POC)
  • 7.4. Market Analysis, Insights and Forecast - By End User
    • 7.4.1. Hospitals and Clinics
    • 7.4.2. Diagnostic Centers
    • 7.4.3. Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. U.K
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Sexually Transmitted Diseases Testing Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product Type
    • 8.1.1. Instruments
    • 8.1.2. Reagents & Kits
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Chlamydia
    • 8.2.2. Syphilis
    • 8.2.3. Genital Herpes
    • 8.2.4. Gonorrhea
    • 8.2.5. Human Immunodeficiency Virus
    • 8.2.6. Human Papillomavirus (HPV)
    • 8.2.7. Others
  • 8.3. Market Analysis, Insights and Forecast - By Setting
    • 8.3.1. Laboratory Testing
    • 8.3.2. Point-of Care (POC)
  • 8.4. Market Analysis, Insights and Forecast - By End User
    • 8.4.1. Hospitals and Clinics
    • 8.4.2. Diagnostic Centers
    • 8.4.3. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. Japan
    • 8.5.2. China
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Sexually Transmitted Diseases Testing Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product Type
    • 9.1.1. Instruments
    • 9.1.2. Reagents & Kits
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Chlamydia
    • 9.2.2. Syphilis
    • 9.2.3. Genital Herpes
    • 9.2.4. Gonorrhea
    • 9.2.5. Human Immunodeficiency Virus
    • 9.2.6. Human Papillomavirus (HPV)
    • 9.2.7. Others
  • 9.3. Market Analysis, Insights and Forecast - By Setting
    • 9.3.1. Laboratory Testing
    • 9.3.2. Point-of Care (POC)
  • 9.4. Market Analysis, Insights and Forecast - By End User
    • 9.4.1. Hospitals and Clinics
    • 9.4.2. Diagnostic Centers
    • 9.4.3. Others
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Sexually Transmitted Diseases Testing Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product Type
    • 10.1.1. Instruments
    • 10.1.2. Reagents & Kits
  • 10.2. Market Analysis, Insights and Forecast - By Application
    • 10.2.1. Chlamydia
    • 10.2.2. Syphilis
    • 10.2.3. Genital Herpes
    • 10.2.4. Gonorrhea
    • 10.2.5. Human Immunodeficiency Virus
    • 10.2.6. Human Papillomavirus (HPV)
    • 10.2.7. Others
  • 10.3. Market Analysis, Insights and Forecast - By Setting
    • 10.3.1. Laboratory Testing
    • 10.3.2. Point-of Care (POC)
  • 10.4. Market Analysis, Insights and Forecast - By End User
    • 10.4.1. Hospitals and Clinics
    • 10.4.2. Diagnostic Centers
    • 10.4.3. Others
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Abbott
      • 11.2.1.1. Overview,
      • 11.2.1.2. Product,
      • 11.2.1.3. SWOT Analysis,
      • 11.2.1.4. Recent Developments,
      • 11.2.1.5. Strategies,
      • 11.2.1.6. financials (Based on Availability)
    • 11.2.2. F. Hoffmann-La Roche Ltd
      • 11.2.2.1. Overview,
      • 11.2.2.2. Product,
      • 11.2.2.3. SWOT Analysis,
      • 11.2.2.4. Recent Developments,
      • 11.2.2.5. Strategies,
      • 11.2.2.6. financials (Based on Availability)
    • 11.2.3. Becton, Dickinson and Company (BD)
      • 11.2.3.1. Overview,
      • 11.2.3.2. Product,
      • 11.2.3.3. SWOT Analysis,
      • 11.2.3.4. Recent Developments,
      • 11.2.3.5. Strategies,
      • 11.2.3.6. financials (Based on Availability)
    • 11.2.4. Hologic, Inc.
      • 11.2.4.1. Overview,
      • 11.2.4.2. Product,
      • 11.2.4.3. SWOT Analysis,
      • 11.2.4.4. Recent Developments,
      • 11.2.4.5. Strategies,
      • 11.2.4.6. financials (Based on Availability)
    • 11.2.5. Danaher Corporation
      • 11.2.5.1. Overview,
      • 11.2.5.2. Product,
      • 11.2.5.3. SWOT Analysis,
      • 11.2.5.4. Recent Developments,
      • 11.2.5.5. Strategies,
      • 11.2.5.6. financials (Based on Availability)
    • 11.2.6. Thermo Fisher Scientific Inc.
      • 11.2.6.1. Overview,
      • 11.2.6.2. Product,
      • 11.2.6.3. SWOT Analysis,
      • 11.2.6.4. Recent Developments,
      • 11.2.6.5. Strategies,
      • 11.2.6.6. financials (Based on Availability)
    • 11.2.7. bioMerieux, Inc.
      • 11.2.7.1. Overview,
      • 11.2.7.2. Product,
      • 11.2.7.3. SWOT Analysis,
      • 11.2.7.4. Recent Developments,
      • 11.2.7.5. Strategies,
      • 11.2.7.6. financials (Based on Availability)
    • 11.2.8. Bio-Rad Laboratories, Inc.
      • 11.2.8.1. Overview,
      • 11.2.8.2. Product,
      • 11.2.8.3. SWOT Analysis,
      • 11.2.8.4. Recent Developments,
      • 11.2.8.5. Strategies,
      • 11.2.8.6. financials (Based on Availability)
    • 11.2.9. DiaSorin Inc.
      • 11.2.9.1. Overview,
      • 11.2.9.2. Product,
      • 11.2.9.3. SWOT Analysis,
      • 11.2.9.4. Recent Developments,
      • 11.2.9.5. Strategies,
      • 11.2.9.6. financials (Based on Availability)

List of Tables

  • Table 01: Global Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Product Type, 2021-2034
  • Table 02: Global Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 03: Global Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Setting, 2021-2034
  • Table 04: Global Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By End User, 2021-2034
  • Table 05: Global Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Region, 2021-2034
  • Table 06: North America Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Product Type, 2021-2034
  • Table 07: North America Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 08: North America Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Setting, 2021-2034
  • Table 09: North America Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By End User, 2021-2034
  • Table 10: North America Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 11: Europe Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Product Type, 2021-2034
  • Table 12: Europe Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 13: Europe Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Setting, 2021-2034
  • Table 14: Europe Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By End User, 2021-2034
  • Table 15: Europe Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2021-2034
  • Table 16: Asia Pacific Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Product Type, 2021-2034
  • Table 17: Asia Pacific Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 18: Asia Pacific Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Setting, 2021-2034
  • Table 19: Asia Pacific Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By End User, 2021-2034
  • Table 20: Asia Pacific Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2021-2034
  • Table 21: Latin America Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Product Type, 2021-2034
  • Table 22: Latin America Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 23: Latin America Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Setting, 2021-2034
  • Table 24: Latin America Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By End User, 2021-2034
  • Table 25: Latin America Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2021-2034
  • Table 26: Middle East & Africa Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Product Type, 2021-2034
  • Table 27: Middle East & Africa Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 28: Middle East & Africa Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Setting, 2021-2034
  • Table 29: Middle East & Africa Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By End User, 2021-2034
  • Table 30: Middle East & Africa Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2021-2034

List of Figures

  • Figure 01: Global Sexually Transmitted Diseases Testing Market Value Share (%), By Product Type, 2025 & 2034
  • Figure 02: Global Sexually Transmitted Diseases Testing Market Value Share (%), By Application, 2025 & 2034
  • Figure 03: Global Sexually Transmitted Diseases Testing Market Value Share (%), By Setting, 2025 & 2034
  • Figure 04: Global Sexually Transmitted Diseases Testing Market Value Share (%), By End User, 2025 & 2034
  • Figure 05: Global Sexually Transmitted Diseases Testing Market Value Share (%), By Region, 2025 & 2034
  • Figure 06: North America Sexually Transmitted Diseases Testing Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 07: North America Sexually Transmitted Diseases Testing Market Value Share (%), by Product Type, 2025
  • Figure 08: North America Sexually Transmitted Diseases Testing Market Value (USD billion), by Application, 2025 & 2034
  • Figure 09: North America Sexually Transmitted Diseases Testing Market Value Share (%), by Application, 2025
  • Figure 10: North America Sexually Transmitted Diseases Testing Market Value (USD billion), by Setting, 2025 & 2034
  • Figure 11: North America Sexually Transmitted Diseases Testing Market Value Share (%), by Setting, 2025
  • Figure 12: North America Sexually Transmitted Diseases Testing Market Value (USD billion), by End User, 2025 & 2034
  • Figure 13: North America Sexually Transmitted Diseases Testing Market Value Share (%), by End User, 2025
  • Figure 14: North America Sexually Transmitted Diseases Testing Market Value (USD billion), by Country, 2025 & 2034
  • Figure 15: North America Sexually Transmitted Diseases Testing Market Value Share (%), by Country, 2025
  • Figure 16: Europe Sexually Transmitted Diseases Testing Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 17: Europe Sexually Transmitted Diseases Testing Market Value Share (%), by Product Type, 2025
  • Figure 18: Europe Sexually Transmitted Diseases Testing Market Value (USD billion), by Application, 2025 & 2034
  • Figure 19: Europe Sexually Transmitted Diseases Testing Market Value Share (%), by Application, 2025
  • Figure 20: Europe Sexually Transmitted Diseases Testing Market Value (USD billion), by Setting, 2025 & 2034
  • Figure 21: Europe Sexually Transmitted Diseases Testing Market Value Share (%), by Setting, 2025
  • Figure 22: Europe Sexually Transmitted Diseases Testing Market Value (USD billion), by End User, 2025 & 2034
  • Figure 23: Europe Sexually Transmitted Diseases Testing Market Value Share (%), by End User, 2025
  • Figure 24: Europe Sexually Transmitted Diseases Testing Market Value (USD billion), by Country/Sub-Region, 2025 & 2034
  • Figure 25: Europe Sexually Transmitted Diseases Testing Market Value Share (%), by Country/Sub-Region, 2025
  • Figure 26: Asia Pacific Sexually Transmitted Diseases Testing Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 27: Asia Pacific Sexually Transmitted Diseases Testing Market Value Share (%), by Product Type, 2025
  • Figure 28: Asia Pacific Sexually Transmitted Diseases Testing Market Value (USD billion), by Application, 2025 & 2034
  • Figure 29: Asia Pacific Sexually Transmitted Diseases Testing Market Value Share (%), by Application, 2025
  • Figure 30: Asia Pacific Sexually Transmitted Diseases Testing Market Value (USD billion), by Setting, 2025 & 2034
  • Figure 31: Asia Pacific Sexually Transmitted Diseases Testing Market Value Share (%), by Setting, 2025
  • Figure 32: Asia Pacific Sexually Transmitted Diseases Testing Market Value (USD billion), by End User, 2025 & 2034
  • Figure 33: Asia Pacific Sexually Transmitted Diseases Testing Market Value Share (%), by End User, 2025
  • Figure 34: Asia Pacific Sexually Transmitted Diseases Testing Market Value (USD billion), by Country/Sub-Region, 2025 & 2034
  • Figure 35: Asia Pacific Sexually Transmitted Diseases Testing Market Value Share (%), by Country/Sub-Region, 2025
  • Figure 36: Latin America Sexually Transmitted Diseases Testing Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 37: Latin America Sexually Transmitted Diseases Testing Market Value Share (%), by Product Type, 2025
  • Figure 38: Latin America Sexually Transmitted Diseases Testing Market Value (USD billion), by Application, 2025 & 2034
  • Figure 39: Latin America Sexually Transmitted Diseases Testing Market Value Share (%), by Application, 2025
  • Figure 40: Latin America Sexually Transmitted Diseases Testing Market Value (USD billion), by Setting, 2025 & 2034
  • Figure 41: Latin America Sexually Transmitted Diseases Testing Market Value Share (%), by Setting, 2025
  • Figure 42: Latin America Sexually Transmitted Diseases Testing Market Value (USD billion), by End User, 2025 & 2034
  • Figure 43: Latin America Sexually Transmitted Diseases Testing Market Value Share (%), by End User, 2025
  • Figure 44: Latin America Sexually Transmitted Diseases Testing Market Value (USD billion), by Country/Sub-Region, 2025 & 2034
  • Figure 45: Latin America Sexually Transmitted Diseases Testing Market Value Share (%), by Country/Sub-Region, 2025
  • Figure 46: Middle East & Africa Sexually Transmitted Diseases Testing Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 47: Middle East & Africa Sexually Transmitted Diseases Testing Market Value Share (%), by Product Type, 2025
  • Figure 48: Middle East & Africa Sexually Transmitted Diseases Testing Market Value (USD billion), by Application, 2025 & 2034
  • Figure 49: Middle East & Africa Sexually Transmitted Diseases Testing Market Value Share (%), by Application, 2025
  • Figure 50: Middle East & Africa Sexually Transmitted Diseases Testing Market Value (USD billion), by Setting, 2025 & 2034
  • Figure 51: Middle East & Africa Sexually Transmitted Diseases Testing Market Value Share (%), by Setting, 2025
  • Figure 52: Middle East & Africa Sexually Transmitted Diseases Testing Market Value (USD billion), by End User, 2025 & 2034
  • Figure 53: Middle East & Africa Sexually Transmitted Diseases Testing Market Value Share (%), by End User, 2025
  • Figure 54: Middle East & Africa Sexually Transmitted Diseases Testing Market Value (USD billion), by Country/Sub-Region, 2025 & 2034
  • Figure 55: Middle East & Africa Sexually Transmitted Diseases Testing Market Value Share (%), by Country/Sub-Region, 2025